Opendata, web and dolomites

Clarity SIGNED

Real-time renal diagnostic to prevent ICU-acquired Acute Kidney Injury (AKI).

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Clarity project word cloud

Explore the words cloud of the Clarity project. It provides you a very rough idea of what is the project "Clarity" about.

days    organisation    plan    tested    curative    renalsense    medical    57    prevent    electronic    balance    prevalent    market    million    patients    icu    patient    disease    introduces    renal    care    nursing    prevention    fluctuations    requiring    therapy    mortality    time    acquired    changing    injury    interprets    industrialization    efficacy    hospital    transmitting    risk    rapid    secured    decade    significantly    ing    hours    university    treatment    strategy    practiced    trade    composition    provides    unfortunately    kidney    consistent    24    acute    flow    pittsburgh    outcomes    limit    develops    feasibility    worldwide    volume    critical    feasible    rms    records    basis    patented    alerts    people    variably    trials    fluid    urine    serious    function    data    accurate    herzog    sensor    die    sign    intensive    morbidity    burden    showed    13    automatically    staff    invaluable    lost    global    intervention    additional    gbd    aki    clinical    monitoring    facilitates    clarity    reflects    hadassah   

Project "Clarity" data sheet

The following table provides information about the project.

Coordinator
RENAL SENSE LTD 

Organization address
address: HAMARPE 3
city: JERUSALEM
postcode: 91450
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-11-01   to  2020-02-29

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    RENAL SENSE LTD IL (JERUSALEM) coordinator 50˙000.00

Map

 Project objective

Intensive Care Unit (ICU)-acquired Acute Kidney Injury (AKI) is a prevalent and serious problem, associated with significantly increased morbidity and mortality. According to the Global Burden of Disease (GBD), each year around 1.7 million people worldwide are estimated to die from AKI. AKI develops in over 57% of ICU patients, requiring an average of 3.5 additional hospital days and €13,000 of additional hospital costs per patient. The best treatment for AKI is prevention. Although there is no curative therapy for AKI, research over the past decade identified various means to prevent or limit AKI. Unfortunately, these are not widely known and are variably practiced worldwide resulting in lost opportunities to improve the care and outcomes of patients with AKI. RenalSense introduces Clarity RMS™, a critical care monitoring system that continuously measures urine flow, automatically transmitting to the medical staff real-time data and alerts of fluctuations, on a 24/7 basis. Using patented sensor technology, Clarity measures, analyses and interprets the continuously changing composition and flow volume of urine. This information, which reflects changes in renal function, provides an early sign of AKI risk and facilitates rapid intervention. In addition, it is invaluable for monitoring treatment efficacy and managing fluid balance. The system has been tested during clinical trials with Herzog hospital, Hadassah Medical Organisation and University of Pittsburgh. Analysis of 1,000 study hours showed that electronic measurements with Clarity were more consistent, reliable and accurate than nursing records. During the feasibility assessment, RenalSense will establish a go-to-market strategy, as well as a feasible product development plan and industrialization strategy. The plan for the large-scale clinical trials will be defined, and the participants secured.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CLARITY" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CLARITY" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DNA DS (2019)

DNA Data storage

Read More  

ERGOVIAkinematix (2018)

New wearable measurement devices for Industry 4.0 based on gaming motion-capture system

Read More  

Magnesys (2019)

Efficient filtering of metallic impurities in food processing

Read More